About the Authors

Cuiqing Liu

Affiliations Department of Physiology, Hangzhou Normal University, Hangzhou, China, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States of America

Rajagopal Desikan

Affiliation InVasc Therapeutics, Tucker, Georgia, United States of America

Zhekang Ying

Affiliation Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States of America

Liubov Gushchina

Affiliation Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States of America

Thomas Kampfrath

Affiliation Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States of America

Jeffrey Deiuliis

Affiliation Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States of America

Aixia Wang

Affiliation Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States of America

Xiaohua Xu

Affiliation Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States of America

Jixin Zhong

Affiliation Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States of America

Xiaoquan Rao

Affiliation Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States of America

Qinghua Sun

Affiliation Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States of America

Andrei Maiseyeu

Affiliation Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States of America

Sampath Parthasarathy

Affiliation Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States of America

Sanjay Rajagopalan

sanjay.rajagopalan@osumc.edu

Affiliation Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States of America

Competing Interests

The authors would like to acknowledge that this work was made possible via a collaborative effort between InVasc Therapeutics and Ohio State University. InVasc Therapeutics is a non-publicly traded private company based in Columbus, OH. Dr. Rajagopal Desiakan, one of the co-authors, was fully employed by InVasc Therapeutics at the time of this work. Cuiqing Liu was a co-founder of the company along with Sampath Parthasarathy and have patents on INV315 and related myeloperoxidase inhibitors that are currently pending approval at the US Patent and Trade office. The molecules that were investigated in this work were licensed for use by InVasc Therapeutics. Funding for this work was through a National Institutes of Health SBIR grant (R43HL103269) awarded to InVasc Therapeutics with OSU as a subcontractor. Neither Dr. Parthasarathy nor Cuiqing Liu are employees of InVasc but do function in an advisory role to the company. The authors declare that the relationship with InVasc does not alter their adherence to all of the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: CL ZY SP SR. Performed the experiments: CL ZY LG TK JD AW XX AM. Analyzed the data: JZ XR. Contributed reagents/materials/analysis tools: RD. Wrote the paper: CL QS SR.